We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Testing for Infectious Diseases Incorporates Automated PCR System

By LabMedica International staff writers
Posted on 26 May 2009
A fully automated, integrated system for rapid testing for infectious diseases incorporates a new polymerase chain reaction (PCR) system.

The system, called Jaguar, is an integrated bench-top molecular diagnostic system that provides hands-off operation. The system incorporates clinical sample preparation, nucleic acid extraction, and microfluidic real-time polymerase chain reaction (PCR) amplification, and detection. The self-contained workstation is designed to accommodate on-demand and batch workflows. It requires minimal laboratory space and minimal skill levels to generate up to 24 real-time PCR results in under two hours.

Image: The Jaguar benchtop, molecular diagnostic system (Photo courtesy of HandyLab).
Image: The Jaguar benchtop, molecular diagnostic system (Photo courtesy of HandyLab).

BD Diagnostics (Franklin Lakes, NJ, USA), a segment of BD (Becton, Dickinson and Company), and HandyLab, Inc. (Ann Harbor, MI, USA) have entered into an exclusive agreement for BD to commercialize its molecular assays on a new BD MAX system, an automated molecular diagnostic testing platform in development using HandyLab's Jaguar instrument. BD will focus initially on its BD GeneOhm line of molecular assays to detect major pathogens associated with healthcare-associated infections (HAIs).

BD produces rapid molecular test methods to help detect major HAI-associated pathogens including methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, vancomycin-resistant Enterococcus and toxigenic Clostridium difficile.

HandyLab develops, manufactures, and sells novel molecular diagnostic products including real time microfluidic PCR technology. HandyLab's platform reduces the time, cost, and complexity of testing while improving the quality of results.

Related Links:

BD Diagnostics
HandyLab, Inc



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette

Latest Molecular Diagnostics News

Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
26 May 2009  |   Molecular Diagnostics

Urine Test Diagnoses Early-Stage Prostate Cancer
26 May 2009  |   Molecular Diagnostics

New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
26 May 2009  |   Molecular Diagnostics